SBIR/STTR Research Award
Not Available
Award amount
$196,192Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Gencia Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- DNSPBR3SME61
- Solicitation number
- PHS2010-1
- Topic code
- NCI
Research abstract
Bioenergetic dysfunction is a well- recognized feature of most (< 97%) metastasizing tumors. Dysfunction of major cell proliferation controllers mutated in the majority of neoplasms, such as the p53, Ras, Myc, PI3K/Akt pathways, results in suppression of mitochondrial oxidative phosphorylation (OXPHOS) and in activation of glycolysis, known as the Warburg effect, which contributes to the resistance to apoptosis. Gencia has developed a recombinant form of human TFAM, the mitochondrial transcription factor A (rhTFAM), modified to allow it to traverse cellular barriers and to be specifically imported into the mitochondria.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Protein Biologic for the Treatment of Sepsis
- The Energetics of Cognitive Performmance: Regulation of Neuronal Adenosine Triphosphate Production
- Mitochondrial Genome Replacement Therapy (MGRT)
- Anti-Aging Mitochondrial Protein Therapy for Alzheimer?s Disease and Sarcopenia
- Mitochondrial Expression of Therapeutic Proteins
Research funding history
11 SBIR/STTR records share this UEI (2003–2010). Reported award amounts total $4,175,422. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense